• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性淋巴细胞白血病患者接种水痘疫苗的经验

Experience of varicella vaccination in acute lymphoplastic leukaemia.

作者信息

Lou J, Tan A M, Tan C K

机构信息

Department of Paediatrics, Tan Tock Seng Hospital, Singapore.

出版信息

Singapore Med J. 1996 Dec;37(6):607-10.

PMID:9104061
Abstract

Varicella is a common benign childhood illness. Rarely, serious complications arise. Immunocompromised patients usually suffer a more serious form of the illness. It is therefore prudent to prevent the infection in this group of patients. Varicella vaccination has been proven by several workers to be effective in both healthy children and adults as well as in leukaemic children. As the vaccine had not been licensed for sale in Singapore, we could only import 10 doses of the vaccine under special license. This was given to 8 leukaemic children. Of this, 5 seroconverted after the first dose. Two patients had the benefit of a repeat vaccination 3 months later. Both subsequently seroconverted. Two of the patients died from a relapse of the illness, a year and 2 years after the vaccination. None of the patients developed any side effects of fever and pain or varicella or zoster after the immunisation even though there was close contact with chicken pox. Although the study sample was small, it appeared that the vaccine was safe and efficacious in leukaemic children, especially after a 2-dose injection.

摘要

水痘是一种常见的儿童良性疾病。严重并发症很少出现。免疫功能低下的患者通常会患更严重的疾病形式。因此,预防这组患者感染是明智的。几位研究人员已证明水痘疫苗对健康儿童和成人以及白血病儿童均有效。由于该疫苗在新加坡未获销售许可,我们只能在特别许可下进口10剂疫苗。这10剂疫苗给了8名白血病儿童。其中,5名儿童在接种第一剂后血清转化。两名患者在3个月后受益于重复接种。两人随后均血清转化。两名患者在接种疫苗一年和两年后因疾病复发死亡。尽管与水痘患者密切接触,但没有患者在免疫接种后出现发热、疼痛、水痘或带状疱疹等任何副作用。虽然研究样本较小,但疫苗似乎对白血病儿童是安全有效的,尤其是在接种两剂后。

相似文献

1
Experience of varicella vaccination in acute lymphoplastic leukaemia.急性淋巴细胞白血病患者接种水痘疫苗的经验
Singapore Med J. 1996 Dec;37(6):607-10.
2
Chickenpox vaccines: new drugs. A favourable risk-benefit balance in some situations.水痘疫苗:新药。在某些情况下风险效益比良好。
Prescrire Int. 2005 Jun;14(77):85-91.
3
[Vaccination of chickenpox in children with acute lymphoblastic leukaemia].[急性淋巴细胞白血病患儿的水痘疫苗接种]
Enferm Infecc Microbiol Clin. 1999 Apr;17(4):162-5.
4
One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?一剂水痘疫苗无法预防学校爆发疫情:是时候接种第二剂了吗?
Pediatrics. 2006 Jun;117(6):e1070-7. doi: 10.1542/peds.2005-2085.
5
Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.两剂水痘疫苗接种方案对癌症患儿的免疫原性
Eur J Haematol. 2004 May;72(5):353-7. doi: 10.1111/j.1600-0609.2004.00216.x.
6
A review of the varicella vaccine in immunocompromised individuals.免疫功能低下个体中水痘疫苗的综述。
Int J Infect Dis. 2004 Sep;8(5):259-70. doi: 10.1016/j.ijid.2003.09.006.
7
Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.接种疫苗能否消除水痘?德国儿童普遍接种水痘疫苗的潜在临床和经济影响。
Med Microbiol Immunol. 2002 Oct;191(2):89-96. doi: 10.1007/s00430-002-0123-4. Epub 2002 Aug 29.
8
Varicella vaccine in non-immune household contacts of children with cancer or leukaemia.癌症或白血病患儿非免疫家庭接触者的水痘疫苗
J Paediatr Child Health. 1999 Aug;35(4):341-5.
9
Routine immunisation against chickenpox. Is it time?常规水痘免疫接种。是时候了吗?
J Singapore Paediatr Soc. 1992;34(1-2):57-66.
10
Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.给目前或过去CD4(+) T细胞显著减少的HIV感染儿童接种水痘活疫苗。
J Infect Dis. 2006 Jul 15;194(2):247-55. doi: 10.1086/505149. Epub 2006 Jun 14.

引用本文的文献

1
Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.用于儿童和成人水痘(带状疱疹)暴露后预防的疫苗。
Cochrane Database Syst Rev. 2014 Jun 23;2014(6):CD001833. doi: 10.1002/14651858.CD001833.pub3.